Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd announced new findings from its collaboration with Tessara Therapeutics, showing that Exenatide significantly reduces neurofilament light chain expression, a marker of neuronal damage, in Alzheimer’s Disease models. This suggests Exenatide’s potential in mitigating early neurodegenerative processes and enhancing its therapeutic value in treating Alzheimer’s Disease, despite uncertainties regarding the continuation of the Tessara collaboration due to potential board changes.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company focused on the development and commercialization of Exenatide for neurological conditions related to raised intracranial pressure.
Average Trading Volume: 65,477
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$8.64M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.